Intuitive Surgical, Inc. (NASDAQ:ISRG) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have received a consensus rating of “Moderate Buy” from the twenty brokerages that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $446.45.

Several analysts have issued reports on the stock. Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Robert W. Baird lifted their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Finally, Citigroup increased their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd.

Intuitive Surgical Trading Up 0.6 %

Shares of ISRG opened at $489.07 on Tuesday. Intuitive Surgical has a 12-month low of $254.85 and a 12-month high of $496.18. The company has a market cap of $173.47 billion, a PE ratio of 88.28, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. The stock has a 50-day moving average price of $469.05 and a 200-day moving average price of $426.06.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the firm posted $1.18 EPS. The firm’s revenue was up 14.5% compared to the same quarter last year. As a group, analysts predict that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares in the company, valued at $5,441,507.50. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors and hedge funds have recently made changes to their positions in the business. Gilbert & Cook Inc. lifted its position in Intuitive Surgical by 6.5% during the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after purchasing an additional 211 shares in the last quarter. TrinityPoint Wealth LLC grew its stake in shares of Intuitive Surgical by 21.5% during the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after acquiring an additional 191 shares during the period. Hilltop Holdings Inc. increased its holdings in Intuitive Surgical by 36.2% in the 4th quarter. Hilltop Holdings Inc. now owns 5,387 shares of the medical equipment provider’s stock worth $1,817,000 after acquiring an additional 1,432 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in Intuitive Surgical by 53.5% during the 4th quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock worth $21,541,000 after acquiring an additional 22,264 shares during the period. Finally, Mitchell Sinkler & Starr PA lifted its holdings in Intuitive Surgical by 13.7% during the fourth quarter. Mitchell Sinkler & Starr PA now owns 1,622 shares of the medical equipment provider’s stock valued at $547,000 after purchasing an additional 195 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.